Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|March 8, 2017
Report of the 6th International Workshop on PET in lymphomaCristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|March 8, 2017
Report of the 6th International Workshop on PET in lymphomaCristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Pageof 15